Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

v3.22.4
Stockholders’ Equity (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Feb. 08, 2022
Sep. 03, 2021
Jul. 19, 2021
Jun. 19, 2021
Jul. 02, 2020
Jan. 31, 2021
Jun. 18, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 19, 2018
Subsidiary, Sale of Stock [Line Items]                    
Net proceeds from public offering of common stock               $ 5,580,000  
Research and development expense               $ 16,678,000 $ 14,583,000  
Common stock, shares outstanding               217,264,526 216,269,450  
Number of warrant to purchase of common stock               238,000    
Class of warrant or right, exercise price               $ 0.75    
Common Stock [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Stock issued during new issued, shares                 3,023,147  
Shares converted     2,000              
Shares issued upon conversion     8,436,000              
Series B Preferred Stock [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Preferred stock shares authorized               10,000,000   8,000
Preferred stock par value               $ 0.001    
Shares converted       4,218     143      
Common stock, shares outstanding       1,687,200            
Common Stock [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Shares converted             286,000      
Restated Exclusive License Agreement [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Milestone fee $ 100,000                  
License fee 50,000                  
Research and development expense $ 291,000                  
Stock issued during new issued, shares 400,000                  
Share price $ 0.728                  
Restated Exclusive License Agreement [Member] | Unregistered Shares [Member] | Rutgers [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Business acquisition, equity iterest issued or issuable, shares 400,000                  
Aquarius Merger Agreement [Member] | Unregistered Shares [Member] | Holders Of Aquarius Biotechnologies Inc [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Business acquisition, equity iterest issued or issuable, shares   1,500,000                
Research and development expense   $ 1,200,000                
Share price   $ 0.80                
Underwritten Public Offering [Member] | Sales Agreement [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Aggregate offering price for sale of stock         $ 50,000,000     $ 44,247,000    
Sale of stock percentage         3.00%          
Sale of stock shares           3,023,147        
Proceeds from issuance of common stock           $ 5,753,000        
Net proceeds from public offering of common stock           $ 5,580,000